Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins. The firm has developed Biochaperone proprietary technological platform to enhance the effectiveness of therapeutic proteins. The company's product pipeline includes biochaprone lispro, biochaparone combo, biochaparone human glucagon etc. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
Lyon, 69003, France